IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney disease: atrasentan shows promise in IgA nephropathy trial
Disease control CompletedThis study tested a drug called atrasentan in 54 adults with IgA nephropathy, a kidney disease. Participants were already on standard treatments, including SGLT2 inhibitors. The goal was to see if atrasentan could further reduce protein in the urine, a sign of kidney damage, comp…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 08:54 UTC
-
New drug combo shows promise for slowing kidney disease
Disease control CompletedThis study tested whether adding the drug sparsentan to a standard SGLT2 inhibitor can safely reduce protein leakage in the urine of adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The 48 participants had already been on stable doses of both an SGLT…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 08:49 UTC
-
New drug shows promise for kidney disease in early trial
Disease control CompletedThis study tested a new medicine called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo, and researchers tracked s…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
First human test of VIS649 drug for kidney disease shows safety
Knowledge-focused CompletedThis early-stage study tested a new drug called VIS649 in 51 healthy adults to see if it is safe and how the body processes it. VIS649 is designed to target a protein linked to IgA nephropathy, a kidney disease. The study compared different single doses of the drug against a plac…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 08:50 UTC